Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Going back to the IEL cells for a moment, in Crohns disease and ulcerative colitis (UC) these cells can start to attack the gut lining itself, this further creates a cytotoxic environment, which can further exacerbate IELs to produce pro-inflammatory proteins, this can lead to a compromised intestinal lining, along with alterations in the gut microbiome
This effect begins with the very first dose, though it strengthens over subsequent weeks as drug levels accumulate
UK Office United Laborartories Ltd
GLP-1 agonists are currently FDA-approved for the treatment of obesity due to their weight loss effects
New treatments like Retatrutide, which is currently finishing Phase 3 clinical trials, are also expected to offer similar benefits and expand treatment options for those with metabolic challenges
